Chidamide

西达本胺

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameChidamide
Drug Alias NameTucidinostatChidemidechidaniline爱谱沙Epidaza +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGTPase Ras inhibitorsProto-oncogene proteins c-akt inhibitorsMitogen-activated protein kinase inhibitors +[7] 
TargetsGTPase RasProto-oncogene proteins c-aktMitogen-activated protein kinase +[7] 
Therapy Area/IndicationsThrombocytopeniaNeoplasms, ExperimentalSmall Cell Lung Carcinoma +[18] 
Global Approved IndicationsLymphoma, T-Cell, PeripheralLeukemia, T-Cell
Approved Indications in ChinaLymphoma, T-Cell, Peripheral
Original Approved Country/TerritoryMainland China
Original Approved Date2014/12/23
Country/TerritoryTaiwanSouth KoreaMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShenzhen Chipscreen Biosciences Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGntbmGreat Novel Therapeutics Biotech & Medicals CorpHuya Bioscience International Llc +[14] 
Inactive CompaniesCancer Hospital Of Chinese Academy Of Medical SciencesFirst Hospital Of Jilin UniversityPeking University
Active IndicationsThrombocytopeniaSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[11] 
Inactive IndicationsNeoplasms, ExperimentalCarcinoma, Adenoid CysticLymphoma, B-Cell +[7] 

Other Information

ATC CodeL01XX
Related LinksWikipediaDrugBankKEGG